The genetics company is closing a unit that was once seen as core to its future.

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

The company posted an earnings per share loss of $0.25. Development progress reported for key drugs, including brepocitinib ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Recent developments driving growth in this area make the advanced, AI-supported digitization of pharma pipelines inevitable.

Me, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business challenges, ...

The company said it plans to wind down ongoing clinical trials “as quickly as practical” — and that it was currently ...

Google DeepMind releases AlphaFold 3's source code to academics, marking a significant advance in AI-powered molecular biology and drug discovery, while balancing open science with commercial ...

AlphaFold 3 will significantly impact drug development, but Google's commercial limits might slow it down. It's not hard to ...

Advancing to first-in-human clinical trials requires formulation development to design a successful sterile formulation that ...